MARKET

INBX

INBX

Inhibrx, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.88
+0.06
+0.36%
Opening 10:00 05/07 EDT
OPEN
16.97
PREV CLOSE
16.82
HIGH
17.24
LOW
16.85
VOLUME
7.00K
TURNOVER
--
52 WEEK HIGH
50.97
52 WEEK LOW
14.43
MARKET CAP
601.85M
P/E (TTM)
-7.3519
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6)
Benzinga · 2h ago
72 Biggest Movers From Yesterday
Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares surged 85.8% to settle at $10.22 on above-average volume.
Benzinga · 4h ago
Stocks That Hit 52-Week Lows On Thursday
    During the morning session on Thursday, 67 stocks hit new 52-week lows.
Benzinga · 23h ago
64 Biggest Movers From Yesterday
Gainers
Benzinga · 2d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Benzinga · 2d ago
SEEL, AEZS, SJR and TRCH among midday movers
Gainers: Sigma Labs (SGLB) +162%.Check-Cap (CHEK) +110%.Rubius Therapeutics (RUBY) +69%.Luokung Technology (LKCO) +43%.Shaw Communications (SJR) +38%.RumbleON (RMBL) +38%.Aeterna Zentaris (AEZS) +31%.Baosheng Media (BAOS) +30%.Intec Pharma (NTEC) +29%.GenM...
Seekingalpha · 03/15 16:39
Inhibrx Surpasses 4Q Revenue Estimates; Street Remains Bullish
Inhibrx Inc posted better-than-expected 4Q revenue and also reported Phase 1 results for its therapeutic candidate, INBRX-105. The biotechnology company currently has four clinical development programs. Shares were up about 1.5% in Friday’s after-hours tra...
SmarterAnalyst · 03/14 08:21
Inhibrx's INBRX-105 Shows Dose-Limiting Toxicities In Early-Stage Solid Tumors Study
Inhibrx Inc (NASDAQ: INBX) 
Benzinga · 03/12 16:53
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of INBX. Analyze the recent business situations of Inhibrx, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average INBX stock price target is 40.50 with a high estimate of 50.00 and a low estimate of 28.00.
EPS
Institutional Holdings
Institutions: 51
Institutional Holdings: 15.57M
% Owned: 43.66%
Shares Outstanding: 35.65M
TypeInstitutionsShares
Increased
10
2.26M
New
29
610.95K
Decreased
7
465.86K
Sold Out
9
655.23K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.38%
Pharmaceuticals & Medical Research
+1.05%
Key Executives
Chairman/Chief Executive Officer/Co-Founder/Director
Mark Lappe
Co-Founder/Executive Vice President/Chief Scientific Officer/Director
Brendan Eckelman
Co-Founder/Executive Vice President
Quinn Deveraux
Chief Financial Officer/Primary Contact
Kelly Deck
Executive Vice President
Klaus Wagner
No Data
About INBX
Inhibrx Inc. is a clinical-stage biotechnology company. The Company is focused on developing biologic therapeutics for people with life-threatening conditions. It has a pipeline of novel biologic therapeutic candidates, developed using its single domain antibody (sdAb) platform. Its pipeline includes INBRX-109, INBRX-106, INBRX-105 and INBRX-101. INBRX-109 is a tetravalent death receptor 5 (DR5) agonist being evaluated in patients diagnosed with chondrosarcoma and mesothelioma cancers. INBRX-106 is a hexavalent OX40 agonist being investigated in patients with locally advanced or metastatic solid tumors. INBRX-105 is a precisely engineered tetravalent sdAb based therapeutic candidate, acting both as an antagonist of programmed death ligand 1 (PD-L1) and a conditional agonist of 4-1BB. INBRX-101 is a precisely engineered recombinant human AAT-Fc fusion protein therapeutic candidate, in development for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).

Webull offers kinds of Inhibrx Inc stock information, including NASDAQ:INBX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INBX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INBX stock methods without spending real money on the virtual paper trading platform.